As treatment strategies evolve in cutaneous lupus erythematosus (CLE), physicians are increasingly turning to advanced systemic therapies while evaluating emerging targeted options that may reshape ...

Patients with lupus face a high burden of comorbidities, with the presence of at least one of seven key conditions linked to 55%-60% lower odds of achieving remission or a low disease activity state.

Almost 90% of a cohort of patients with systemic lupus erythematosus reported experiencing depression or depressive symptoms ...

The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus ...

Antimitochondrial antibodies can be detected in patients with systemic lupus erythematosus (SLE) and appear prognostic.

For patients living with Systemic Lupus Erythematosus (SLE), their immune systems mistakenly attack themselves, unleashing ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

Obinutuzumab was superior to placebo for systemic lupus erythematosus in a phase 3 trial, significantly improving SRI-4 ...